Cosmo pharmaceuticals

At Cosmo, we are committed to improve peoples lives by developing products that address unmet medical needs in the fields of gastroenterology, dermatology and healthtech.

Investors

Latest News

12 Apr 2024

Cosmo and Medtronic unveil the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

Read More
20 Mar 2024
AD HOC

Cosmo reports excellent preliminary unaudited Full Year 2023 core financial results – Record guidance for 2024 – Doubles dividend to € 2.00 per share

Read More
19 Mar 2024

Cosmo Pharmaceuticals announces approval of Winlevi® in Australia

Read More

Upcoming Events

30 Apr 2024

Annual Report 2023

Add to Outlook
24 May 2024

Annual General Meeting 2024

Add to Outlook
25 Jul 2024

Half Year Results 2024

Add to Outlook

Latest presentation

21 Mar 2024
Investor Day Full Year Results 2023

Therapeutic Focus

Cosmo’s therapeutic focus is on the treatment of gastrointestinal diseases (including IBD, colonic infections and colorectal cancer – CRC), increase the effectiveness of endoscopic examinations and to treat persistent skin conditions, like acne, and androgenetic alopecia, that have a long-term physical and emotional impact on lives and self-esteem.

Find out more

Our Mission

To improve people’s lives by developing products that address unmet medical needs in the fields of gastroenterology, dermatology and healthtech.

Find out more

Manufacturing

We provide services related to the production of pharmaceutical products as: assessment of manufacturing processes, technology transfer, evaluation of pharmaceutical product stability, testing and release to the market and drafting of the necessary documentation for pharmaceutical products’ registration.

Find out more